Patients with NAFLD showed elevated serum NE concentrations and reduced levels of its inhibitor α1-antitrypsin A1AT, resulting in an NE/A1AT imbalance, a ratio associated with NASH progression (Zang et al., 2016). This evidence concerns the gene SERPINA1 and metabolic dysfunction-associated steatotic liver disease.